Navigation Links
Cell Therapeutics Resubmits Pixantrone NDA to FDA for Consideration of Accelerated Approval
Date:10/24/2011

SEATTLE, Oct. 25, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it has resubmitted the pixantrone New Drug Application ("NDA") to the U.S. Food and Drug Administration's ("FDA") Division of Oncology Drug Products ("DODP") for accelerated approval to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") in patients who failed two or more lines of prior therapy.

CTI had appealed the FDA's Complete Response Letter for the pixantrone NDA based on the results of the PIX301 clinical trial. In May 2011, the FDA's Office of New Drugs ("OND") responded to CTI's appeal recommending that CTI conduct an additional review of radiographs utilizing a new independent panel of radiologists to confirm the response and progression events noted in the pixantrone NDA in order to determine that efficacy had been established.  CTI recently announced that a second independent radiology assessment of response and progression endpoint data confirmed the statistical robustness of the PIX301 efficacy data contained in the NDA.

In June 2011, CTI met with the DODP to review its plans for responding to the items noted in the Complete Response Letter ("CRL"), as well as its plans for addressing the items noted by the OND in response to the appeal. The Company believes the information contained within the resubmitted NDA adequately addresses the recommendations from the OND and items noted in the CRL.

"We believe the resubmitted NDA not only addresses the items in the Complete Response Letter, but confirms the reliability of the initial efficacy results, which we believe demonstrates that pixantrone does provide a clinical benefit to this patient population for which there are no currently approved therapies," said James A. Bianco, M.D., CEO of CTI.

The DODP previously confirmed that the review of the NDA would be completed within six months from the date of resubmission, which should provide C
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
2. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
3. Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients
4. Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018
5. Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
6. Echo Therapeutics Hires Product Development Management Executive
7. Prime Therapeutics Demonstrates Willingness to Show Actual Pharmacy Costs
8. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
9. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
10. Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value
11. Argos Therapeutics Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
(Date:8/27/2015)... Aug. 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first ... the United States in a trial ... stent for blockages in the main artery of the leg. ... and potentially less risk for stent fracture or re-narrowing after ... single-arm, multicenter clinical trial of the BioMimics 3D Stent System ...
(Date:8/27/2015)... 27, 2015 According to ... Research titled "Global Market Study on Urinary Catheters: ... 2021", the urinary catheters market is expected to be valued ... It is anticipated to expand at a CAGR ... Mn by 2021. View full report TOC ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... Mobile Dog Heart Health Tour is heading south to ... health examinations in San Antonio,s McAllister Dog Park. From ... veterinary cardiologists will be performing on site heart screenings ... owners about canine heart disease. (Photo: ...
... Celsis In Vitro, Inc. (Celsis IVT) announced today ... District of Illinois in Chicago has entered a preliminary ... (the Defendants) due to their infringement of U.S. Patent ... California (Nasdaq: LIFE ) is the parent ...
Cached Medicine Technology:Free Dog Heart Checks at McAllister Park 2Free Dog Heart Checks at McAllister Park 3Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 2Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 3
(Date:8/27/2015)... , ... August 27, 2015 , ... In the addiction ... leaving weeks or months later, relapsing and returning again, all at great cost to ... while in sober living homes or soon after leaving facilities who claim to have ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... array of instruments available for quantitative PCR (qPCR) in the last ... higher throughput and reduced operating costs. On the flipside, where do lab managers, ...
(Date:8/27/2015)... ... , ... According to an article published August 19 on Healio, ... educate doctors and patients on the best practices for type 2 diabetes care. The ... the new version is taking into account nearly a decade of recent research data. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney ... The Amazing Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the ... in media outlets as health authorities, and will present a two part seminar entitled, ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... enter the exploding legal marijuana industry with the launch of its Doobster platform, ... legal marijuana to order products from their smart phones and tablets. Well, ...
Breaking Medicine News(10 mins):Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5
... Non-profit organization RAND Corp. has come out with a finding ... who tend to use substance like marijuana, alcohol, and cigarettes ... a younger age, and to have a harder time quitting, ... setting or in groups. ,The results stem from ...
... on the dead skin of visitors' feet is turning into ... // ,Hordes of Turkish spa fish, members of the ... first Fish Reflexology spot at the Underwater World attraction., ... skin are removed by the fish., ,It costs $22 ...
... the scheme 'Assistance for capacity Building', Ministry of ... a maximum //of Rs. 1.50 crores or actual, ... emergency facilities of State Hospitals of towns/cities located ... NHAI, Department of Road Transport and Highways and ...
... Board of Health in a surprise move went back ... change the sex on their birth //certificates, without physically ... seconded by mental health professionals and transgender supporters, who ... discrimination against people who desire to adopt the 'opposite' ...
... A draft report from NHS Institute for Innovation and Improvement ... by GPs and visiting //nurses rather than admitting them in ... a range of conditions regularly seen in Accident and Emergency ... more could be done for reducing the numbers admitted in ...
... by the Department of Radiology at the University of ... the accuracy of diagnosing meniscal tears. ... there is one MR image with an abnormal finding. ... of 174 patients who had knee MR exams then ...
Cached Medicine News:
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Great for small incisions and excision needs...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
2.5mm...
Medicine Products: